Generic Drug Review Costs Still Largely Non-Personnel Related

Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.

Non-personnel costs continue to dominate FDA’s generic drug review expenditures, despite a recent hiring binge.

The agency reported substantial increases in personnel as well as non-personnel costs related to human generic drug activities in its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Already a subscriber?